Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | NSD2 | O96028 | 1/20 | 0.52 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.51 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1901418 | 1.00 | MEN1 (0.52) | MEN1POLBKMT2ANSD2MAP3K5 | |
| SCHEMBL1903872 | 0.91 | APEX1 (0.56) | MEN1POLBKMT2AMAP3K5 | |
| SCHEMBL1903874 | 0.91 | APEX1 (0.56) | MEN1POLBKMT2AMAP3K5 | |
| SCHEMBL1903203 | 0.90 | MAPT (0.56) | MEN1POLBKMT2A | |
| SCHEMBL1905230 | 0.90 | MAPT (0.56) | MEN1POLBKMT2APTPN22 | |
| SCHEMBL1905229 | 0.90 | MAPT (0.56) | MEN1POLBKMT2APTPN22 | |
| SCHEMBL1906468 | 0.90 | PTPN1 (0.56) | MEN1POLBKMT2ANSD2MAP3K5 | |
| SCHEMBL1903205 | 0.90 | MAPT (0.56) | MEN1POLBKMT2A | |
| SCHEMBL1906469 | 0.90 | PTPN1 (0.56) | MEN1POLBKMT2ANSD2MAP3K5 | |
| SCHEMBL1907524 | 0.87 | MAP3K5 (0.59) | MAP3K5PTPN22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947717-B2 | Inhibitors of lethal factor protease | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2011-05-24 | — | — | US | disclosed |
| US-20100016292-A1 | INHIBITORS OF LETHAL FACTOR PROTEASE | THE BURNHAM INSTITUTE (US) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016292-A1 | INHIBITORS OF LETHAL FACTOR PROTEASE | APAF1, F11, SERPINB1 | MEN1 1839/4885POLB 3712/4885KMT2A 3345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.